<DOC>
	<DOCNO>NCT01290549</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , dose-escalation study DCDS4501A administer single agent IV infusion patient relapse refractory hematologic malignancy . In Phase Ib , patient receive DCDS4501A combination rituximab .</brief_summary>
	<brief_title>A Study Escalating Doses DCDS4501A Patients With Relapsed Refractory B-Cell Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia DCDS4501A Combination With Rituximab Patients With Relapsed Refractory B-Cell Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Life expectancy least 12 week History one follow histologicallydocumented hematologic malignancy effective standard therapy exist : indolent non Hodgkin 's lymphoma ( NHL ) , Grade 3b FL , diffuse large Bcell lymphoma ( DLBCL ) , mantle cell lymphoma ( MCL ) , chronic lymphocytic leukemia ( CLL ) All patient ( NHL BCLL ) must least one bidimensionally measurable lesion For men woman childbearing potential ( unless surgically sterile ) : use adequate method contraception oral contraceptive , intrauterine device , barrier method contraception conjunction spermicidal jelly Prior use monoclonal antibody antibodydrug conjugate within 4 week Cycle 1 , Day 1 Treatment radiotherapy , chemotherapeutic agent , treatment investigational anticancer agent within 2 week prior Cycle 1 , Day 1 . Adverse event previous treatment must resolve stabilized prior Cycle 1 , Day 1 , except neuropathy Completion autologous stem cell transplant within 100 day prior Cycle 1 , Day 1 Prior allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>